Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERIDOT: Venglustat in Fabry Disease
NCT05206773Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of venglustat in Fabry disease (FD), sponsored by Sanofi. Started Mar 2022; status: active, not recruiting.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT05206773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206773.